Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $209 from $157 and keeps an Outperform rating on the shares. The firm updated its model following the release of preliminary Q4 results that featured a slight beat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $193 from $157 at Wells Fargo
- Axsome Therapeutics: Strong Commercial Execution and De-Risked Pipeline Support Buy Rating and Long-Term Growth
- Buy Rating on Axsome Therapeutics Backed by Strong Auvelity and Sunosi Outperformance Despite Slower Symbravo Ramp
- Axsome Therapeutics Reports Strong Preliminary 2025 Revenue Growth
- Axsome Therapeutics reports preliminary Q4 revenue $196M, consensus $187.02M